Spontaneous tumor lysis syndrome in a case of B-cell non-Hodgkin's lymphoma
Authors:
Open Access
- 17 June 2014
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 7 (4) , 422-423
Abstract
Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that are usually seen in cancer patients treated with chemotherapy although it can occasionally occur spontaneously without chemotherapy in patients with a high tumor burden. It is due to the rapid lysis of tumor cells resulting in the release of large amounts of intracellular contents in the blood stream. This results in the rapid development of high levels of phosphate, potassium and uric acid accompanied by a profound decrease in serum calcium. TLS usually occurs in bulky tumors with a high turnover such as leukemias and lymphomas. The malignancy can be undiagnosed at the time of development of TLS [1]. In this report we present a case in which the patient presented with spontaneous TLS (STLS) and was later diagnosed with high-grade B-cell non-Hodgkin's lymphoma (NHL).Keywords
This publication has 5 references indexed in Scilit:
- Spontaneous tumour lysis syndromeCanadian Medical Association Journal, 2012
- Nephrotoxicity From Chemotherapeutic Agents: Clinical Manifestations, Pathobiology, and Prevention/TherapySeminars in Nephrology, 2010
- Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutInternational Journal of Medical Sciences, 2007
- Pathophysiology, clinical consequences, and treatment of tumor lysis syndromeThe American Journal of Medicine, 2004
- Efficacy and Safety of Rasburicase (recombinant urate oxidase) for the Prevention and Treatment of Hyperuricemia During Induction Chemotherapy of Aggressive Non-Hodgkin’s Lymphoma: Results of the GRAAL1 (Groupe d’Etude des Lymphomes de l’Adulte Trial on Rasburicase Activity in Adult Lymphoma) StudyJournal of Clinical Oncology, 2003